Hitt M - Search Results

1

Superior tissue-specific expression from tyrosinase and prostate-specific antigen promoters/enhancers in helper-dependent compared with first-generation adenoviral vectors.

Shi CX, Hitt M, Ng P, Graham FL. Shi CX, et al. Among authors: hitt m. Hum Gene Ther. 2002 Jan 20;13(2):211-24. doi: 10.1089/10430340252769743. Hum Gene Ther. 2002. PMID: 11812278

2

Adenovirus E1A under the control of heterologous promoters: wide variation in E1A expression levels has little effect on virus replication.

Hitt MM, Graham FL. Hitt MM, et al. Virology. 1990 Dec;179(2):667-78. doi: 10.1016/0042-6822(90)90134-d. Virology. 1990. PMID: 2146801

3

Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors.

Addison CL, Bramson JL, Hitt MM, Muller WJ, Gauldie J, Graham FL. Addison CL, et al. Among authors: hitt mm. Gene Ther. 1998 Oct;5(10):1400-9. doi: 10.1038/sj.gt.3300731. Gene Ther. 1998. PMID: 9930346

4

Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: in vitro and in vivo production of biologically active interleukin-12.

Bramson J, Hitt M, Gallichan WS, Rosenthal KL, Gauldie J, Graham FL. Bramson J, et al. Among authors: hitt m. Hum Gene Ther. 1996 Feb 10;7(3):333-42. doi: 10.1089/hum.1996.7.3-333. Hum Gene Ther. 1996. PMID: 8835220

5

Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12.

Bramson JL, Hitt M, Addison CL, Muller WJ, Gauldie J, Graham FL. Bramson JL, et al. Among authors: hitt m. Hum Gene Ther. 1996 Oct 20;7(16):1995-2002. doi: 10.1089/hum.1996.7.16-1995. Hum Gene Ther. 1996. PMID: 8930660

6

Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors.

Addison CL, Hitt M, Kunsken D, Graham FL. Addison CL, et al. Among authors: hitt m. J Gen Virol. 1997 Jul;78 ( Pt 7):1653-61. doi: 10.1099/0022-1317-78-7-1653. J Gen Virol. 1997. PMID: 9225042

7

Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination.

Bramson JL, Hitt M, Gauldie J, Graham FL. Bramson JL, et al. Among authors: hitt m. Gene Ther. 1997 Oct;4(10):1069-76. doi: 10.1038/sj.gt.3300508. Gene Ther. 1997. PMID: 9415313

8

Combination therapy with interleukin-2 and wild-type p53 expressed by adenoviral vectors potentiates tumor regression in a murine model of breast cancer.

Pützer BM, Bramson JL, Addison CL, Hitt M, Siegel PM, Muller WJ, Graham FL. Pützer BM, et al. Among authors: hitt m. Hum Gene Ther. 1998 Mar 20;9(5):707-18. doi: 10.1089/hum.1998.9.5-707. Hum Gene Ther. 1998. PMID: 9551618

9

Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models.

Emtage PC, Wan Y, Hitt M, Graham FL, Muller WJ, Zlotnik A, Gauldie J. Emtage PC, et al. Among authors: hitt m. Hum Gene Ther. 1999 Mar 20;10(5):697-709. doi: 10.1089/10430349950018463. Hum Gene Ther. 1999. PMID: 10210138

10

A p75 tumor necrosis factor receptor-specific mutant of murine tumor necrosis factor alpha expressed from an adenovirus vector induces an antitumor response with reduced toxicity.

Marr RA, Hitt M, Gauldie J, Muller WJ, Graham FL. Marr RA, et al. Among authors: hitt m. Cancer Gene Ther. 1999 Sep-Oct;6(5):465-74. doi: 10.1038/sj.cgt.7700068. Cancer Gene Ther. 1999. PMID: 10505857

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

105 results

Search Page

Filters